Learn More About the 2nd Model-Informed Drug Development Summit
The Model-Informed Drug Development Summit unites clinical pharmacology, pharmacometrics, biostatistics, regulatory, and drug development leaders who are advancing the application of model-informed approaches across the pharmaceutical industry. Explore the articles below to gain insight into the latest developments in pharmacokinetic and pharmacodynamic modeling, quantitative systems pharmacology, dose optimization, clinical trial simulation, regulatory engagement, and AI-enabled model development. These are the discussions helping shape how organizations leverage model-informed strategies to accelerate decision-making, reduce development risk, optimize patient outcomes, and bring innovative therapies to market more efficiently.
Browse our selection of expert insights exploring the latest trends, challenges, and opportunities driving the future of model-informed drug development.
Explore the Tools Shaping Modern MIDD
Explore expert articles designed to unpack the science, strategy, and evolving landscape of MIDD. From understanding the role of PBPK and QSP models across the development lifecycle to navigating regulatory expectations and emerging AI-enabled capabilities, these articles provide practical insights into the tools, methodologies, and trends shaping modern drug development. Whether you're building modeling expertise or evaluating how MIDD can drive decision-making within your organization, these resources offer valuable perspectives from leaders across the field.
"I was hoping to learn from others' experience on MIDD and yes I was able to do so."
Senior Director (Head of Solid Tumor in Clinical Pharmacology), Abbvie, 2025 Attendee
"AI-powered structural biology is rapidly maturing as a drug design tool. I am excited to participate in events like this, which bring together perspectives from across the drug development process to accelerate innovation and realize its tremendous potential by highlighting emerging industry challenges and novel solutions."
Senior Investigator and Head of Computational Sciences, AI Proteins, 2026 Speaker
"Connection with more people, more informal discussions that may not be appropriate for ACOP; people were more into sharing experiences here compared to bigger venues like ACOP."
Senior Scientist, Denali Therapeutics, 2025 Speaker
“Engaging audience, small groups are great for networking.”
Director of Clinical Pharmacology, Pfizer, 2025 Speaker
"Good discussion around how to think about MIDD in a time of accelerating innovation"
Director, Amgen, 2025 Attendee
Explore Expert Perspectives on the Future of MIDD
Gain exclusive insights from the leaders shaping the future of MIDD. Our speaker interviews feature candid conversations with industry experts, regulatory specialists, pharmacometricians, and clinical pharmacologists as they share their perspectives on emerging trends, common implementation challenges, and innovative approaches to applying modeling and simulation throughout the drug development lifecycle.
